Human peritoneal mesothelial cells (MC) play an important role in inflammatory processes of the peritoneal cavity by producing various cytokines and chemokines, such as monocyte chemoattractant protein-1 (MCP-1). The present study was designed to assess the effect of the peroxisome proliferator-activated receptor-gamma- (PPAR gamma-) activator rosiglitazone on the mesothelial MCP-1 expression and release. Primary cultures of MC were obtained from omental tissue. MCP-1 antigen concentrations were measured in the cell supernatant by ELISA and MCP-1 mRNA levels by real-time polymerase chain reaction. The presence of PPAR. on MC was assayed in a Western Blot analysis. MC constitutively express PPAR gamma. Activation of this receptor via rosiglitazone (0,1-10 mu mol/L) resulted in significantly reduced amounts of mesothelial MCP-1 release as well as MCP-1 mRNA. The use of the PPAR gamma inhibitor GW-9662 could completely prevent the rosiglitazone effects. Rosiglitazone was also effective in reducing TNF alpha-induced enhanced secretion of MCP-1. Our findings indicate that glitazones are effective in reducing constitutive and TNF alpha-stimulated mesothelial MCP-1 mRNA expression and release.
View all episodes
